Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Endo International plc (ENDP) PT Raised to $18 at Cantor Fitzgerald After Speaking with Physicians
-
Endo International plc (ENDP) PT Raised to $12 at Cantor Fitzgerald
-
Endo International (ENDP) Needs to Show Upward Inflection in Earnings for Cantor to Become More Positive
-
Endo Int'l (ENDP): Good Results But No Visibility, PT To $7 at Cantor
-
Endo International plc (ENDP) PT Lowered to $9 at Cantor Fitzgerald
-
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts Endo International plc (ENDP) at Neutral
-
Pre-Open Stock Movers 03/15: (PIP) (ARNA) (MSCI) Higher; (RUBI) (NPTN) (NMM) Lower (more...)
-
After-Hours Stock Movers 03/14: (PIP) (ARNA) (RST) Higher; (RUBI) (NPTN) (FTD) Lower (more...)
-
Notable Analyst Rating Changes 10/9: (ALB) (MT) (RPD) Upgraded; (FEYE) (TSLA) (PCAR) Downgraded
-
Endo International (ENDP) PT Raised to $92 at Cantor Fitzgerald
-
Cantor Fitzgerald Upgrades Endo Health (ENDP) to Hold
-
Pre-Open Stock Movers 1/24: (BDSI) (OTEX) (JNPR) Higher; (ATOS) (PTCT) (ISRG) Lower (more...)
-
Cantor Cuts Endo Pharmaceuticals (ENDP) to Sell; Lowers PT to $43
-
Notable Analyst Rating Changes 11/06: (ENDP) (CAH) (HST) Upgraded; (RYL) (LF) (THC) Downgraded
-
Cantor Fitzgerald Upgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Hold
-
Cantor Fitzgerald Cuts Endo Pharma (ENDP) to Sell; Not Optimistic Restructuring
-
Notable Analyst Rating Changes 05/08: (LOW) (LULU) (JCP) Upgraded; (VCLK) (CA) (MDLZ) Downgraded
-
Cantor Fitzgerald Downgrades Endo Pharmaceuticals (ENDP) to Hold; Sidelined Ahead of Lidoderm Decision; M&A Unlikely N-T
-
Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
-
Analyst Says Buy the Weakness in Endo Pharma (ENDP) Shares Amid Vancocin Concerns
-
Cantor Fitzgerald Starts Endo Pharma (ENDP) at Buy, $50 Price Target